FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Repaglinide Tablets
Status: Discontinuation
»Therapeutic Categories: Endocrinology/Metabolism

Expand all

Mylan Pharmaceuticals Inc. (New 06/19/2018)

Company Contact Information:
800-796-9526

Presentation Posting Date Related Information
0.5 mg, 100 count bottle (NDC 0378-3121-01) 06/19/2018 The discontinuation of this product is a business decision.
0.5 mg, 500 count bottle (NDC 0378-3121-05) 06/19/2018 The discontinuation of this product is a business decision.
1 mg, 100 count bottle (NDC 0378-3122-01) 06/19/2018 The discontinuation of this product is a business decision.
2 mg, 100 count bottle (NDC 0378-3123-01) 06/19/2018 The discontinuation of this product is a business decision.

Sandoz (New 02/02/2018)

Company Contact Information:
800-525-8747

Presentation Posting Date Related Information
1mg tablets (NDC 0781-5149-01) 02/02/2018

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English